The group concluded that putative NPM1-mutated CD34+CD38- leukemic stem cells consistently express high levels of CD123, a pattern further amplified in cases with concurrent FLT3 mutations, highlighting NPM1-mutated AML as a particularly promising target for anti-CD123 immunotherapies (85). This evidence concerns the gene NPM1 and acute myeloid leukemia.